Karyopharm, deep in debt, to sell itself in bankruptcy

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 02 Nov, 17:07 UTC

The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.

fintechpolicyscience

Sources

• T2Karyopharm, deep in debt, to sell itself in bankruptcyBioPharma Dive / Healthcare Dive / MedTech Dive02 Nov, 17:07